Phreesia (NYSE:PHR) Stock Rating Reaffirmed by JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Phreesia (NYSE:PHR) in a research report report published on Friday morning, Benzinga reports. They currently have a $28.00 target price on the stock.

Several other equities analysts have also issued reports on PHR. DA Davidson raised shares of Phreesia from a neutral rating to a buy rating and boosted their price target for the company from $30.00 to $32.00 in a report on Wednesday, January 17th. Raymond James reissued an outperform rating and issued a $30.00 price target (up previously from $25.00) on shares of Phreesia in a report on Friday. KeyCorp decreased their price target on shares of Phreesia from $40.00 to $30.00 and set an overweight rating for the company in a report on Thursday, December 7th. Needham & Company LLC reissued a buy rating and issued a $29.00 price target on shares of Phreesia in a report on Friday. Finally, Truist Financial started coverage on shares of Phreesia in a report on Monday, February 26th. They issued a buy rating and a $35.00 price target for the company. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, Phreesia currently has an average rating of Moderate Buy and a consensus price target of $32.71.

Phreesia Trading Down 3.5 %

PHR traded down $0.82 during trading on Friday, reaching $22.93. 693,167 shares of the company’s stock were exchanged, compared to its average volume of 545,245. The company’s fifty day moving average price is $25.31 and its 200-day moving average price is $20.99. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.02 and a current ratio of 2.02. Phreesia has a fifty-two week low of $12.05 and a fifty-two week high of $36.13. The firm has a market capitalization of $1.28 billion, a PE ratio of -9.10 and a beta of 0.93.

Phreesia (NYSE:PHR) last released its earnings results on Thursday, March 14th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.02. Phreesia had a negative net margin of 38.42% and a negative return on equity of 52.97%. The firm had revenue of $95.00 million during the quarter, compared to analyst estimates of $93.52 million. During the same quarter in the previous year, the business earned ($0.72) EPS. The business’s quarterly revenue was up 24.0% compared to the same quarter last year. As a group, equities analysts forecast that Phreesia will post -1.47 EPS for the current year.

Insiders Place Their Bets

In other Phreesia news, General Counsel Allison C. Hoffman sold 1,316 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $24.55, for a total transaction of $32,307.80. Following the sale, the general counsel now directly owns 144,464 shares of the company’s stock, valued at approximately $3,546,591.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, General Counsel Allison C. Hoffman sold 1,316 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $24.55, for a total value of $32,307.80. Following the sale, the general counsel now directly owns 144,464 shares of the company’s stock, valued at approximately $3,546,591.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Chaim Indig sold 3,586 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $24.55, for a total transaction of $88,036.30. Following the completion of the sale, the chief executive officer now directly owns 1,280,410 shares in the company, valued at $31,434,065.50. The disclosure for this sale can be found here. Insiders have sold 9,950 shares of company stock valued at $246,213 in the last three months. 5.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Phreesia

Institutional investors and hedge funds have recently modified their holdings of the company. State of Wyoming raised its holdings in Phreesia by 34.6% in the 2nd quarter. State of Wyoming now owns 1,918 shares of the company’s stock valued at $59,000 after acquiring an additional 493 shares during the period. American International Group Inc. raised its holdings in Phreesia by 2.3% in the 4th quarter. American International Group Inc. now owns 26,342 shares of the company’s stock valued at $610,000 after acquiring an additional 591 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Phreesia by 3.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,545 shares of the company’s stock valued at $637,000 after acquiring an additional 710 shares during the period. Capital Impact Advisors LLC raised its holdings in Phreesia by 5.2% in the 2nd quarter. Capital Impact Advisors LLC now owns 15,771 shares of the company’s stock valued at $489,000 after acquiring an additional 781 shares during the period. Finally, Captrust Financial Advisors raised its holdings in Phreesia by 154.6% in the 2nd quarter. Captrust Financial Advisors now owns 1,426 shares of the company’s stock valued at $36,000 after acquiring an additional 866 shares during the period. 94.37% of the stock is owned by institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.